OR · State regulatory reference
Oregon.
Moderate
Oregon telemedicine practice is governed by ORS 677.135–677.141 and OAR chapter 847 division 025; the Oregon Medical Board does not require an in-person visit to establish the provider-patient relationship, applying the same standard of care regardless of modality. Compounding under OAR chapter 855 division 045 adopts the current USP <795>/<797>/<800> chapters. The Board of Pharmacy's Semaglutide/GLP-1 Position Statement (adopted Feb. 6, 2025) limits GLP-1 compounding to the federal 503A(b)(2) exceptions and warns of enforcement — but, like New Jersey's, it restates federal 503A rather than adding a distinctive state rule, and no documented board enforcement order was found.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
An initial visit and prescribing may occur via synchronous audio-video; the Oregon Medical Board does not require an in-person exam to establish the relationship, though the same standard of care applies and out-of-state clinicians need a telemedicine license.
Compounding
OAR chapter 855 division 045 requires adherence to current USP <795>/<797>/<800>; the Board's Feb. 2025 semaglutide position statement restricts GLP-1 compounding to the three federal 503A(b)(2) exceptions and requires FDA-registered, pharmaceutical-grade API with a certificate of analysis.
Sources